{"schema_version":"secwatch.filing_event.v1","accession":"0001178913-25-002008","form_type":"8-K","ticker":"SLXN","cik":"0002022416","company_name":"Silexion Therapeutics Corp","filed_at":"2025-05-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.697216+00:00","generated_at":"2026-05-20T06:51:00.518502+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Silexion SIL204 shows ~90% inhibition in colorectal cells; expands to lung & pancreatic","bullets":["SIL204 inhibited GP2D colorectal cancer cells with ~90% inhibition rate in preclinical study.","Dose-dependent reduction observed in Panc-1 (pancreatic), A427 (lung) cell lines at nanomolar concentrations.","Company to conduct additional lung (NSCLC) cancer cell line study in coming weeks.","KRAS G12D mutation targeted; addresses pancreatic (~90%), colorectal (~45%), and lung (~35%) cancers.","Ilan Hadar cites SIL204's enhanced lipid-conjugate delivery enabling potent activity at low doses."],"urls":{"canonical":"https://secwatch.observer/filing/0001178913-25-002008","json":"https://secwatch.observer/filing/0001178913-25-002008.json","markdown":"https://secwatch.observer/filing/0001178913-25-002008.md","text":"https://secwatch.observer/filing/0001178913-25-002008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/0001178913-25-002008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2022416/000117891325002008/zk2533298.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T06:51:00.518502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}